CHICAGO, and ANN ARBOR, Mich., June 3, 2011 /PRNewswire/ -- Everist Genomics today announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago.
OncoDefender-CRC examines expression levels of a panel of genes extracted from formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and uses a proprietary computer-generated decision rule to stratify patients into 'high-risk' and 'low-risk' categories for assessing likelihood of recurrence.
Accurately identifying Stage I/II colorectal cancer patients who are at risk of recurrence represents a significant unmet medical need as mortality rates for early stage disease are higher than generally realized. "About one in seven patients with Stage I and one in three patients with Stage II colorectal cancer will ultimately experience a recurrence," said Peter F. Lenehan, M.D., Ph.D. Chief Medical Officer of Everist Genomics. "In this sub-population of patients who recur, the associated mortality rates are 50 percent and 80 percent, respectively."
The study confirmed that OncoDefender-CRC was able to differentiate those patients at high risk from those at low risk for cancer recurrence within 3 years after potentially curative surgery more accurately than assessments based on National Comprehensive Cancer Network (NCCN) Guidelines, widely accepted as providing "best practices" in oncology. The study included patient samples from four international sites.
For stages I/II colorectal cancer (n=115), OncoDefender-CRC correctly classified 32/46 cases of recurrence and 38/69 cases of non-recurrence (sensitivity 70%, specif